Matsuoka Naoki, Hasebe Hiruma, Mayama Tetsuji, Fukuchi Takeo
Division of Ophthalmology and Visual Science, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata Prefecture 9518510, Japan ; Murakami General Hospital, Niigata, Japan.
Division of Ophthalmology and Visual Science, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata Prefecture 9518510, Japan.
Case Rep Ophthalmol Med. 2015;2015:181269. doi: 10.1155/2015/181269. Epub 2015 Aug 23.
Purpose. To report the first case of cystoid macular edema (CME) induced by nanoparticle albumin-bound- (nab-) paclitaxel treated with sub-Tenon injections of triamcinolone acetonide (STTA) with detailed long-term follow-up. Case. A 39-year-old Japanese woman with breast cancer presents with decreased vision in both eyes while receiving nab-paclitaxel. Two STTA treatments were administered for persistent CME in her right eye. Central retinal thickness (CRT) of the treated eye decreased after the first STTA, but there was no change after the second STTA. CRT of the other eye and bilateral visual acuity (VA) showed no change after each treatment. However, this patient experienced gradual recovery of visual function after nab-paclitaxel treatment was completed, 3 months after the second STTA. Improvements in VA and CRT did not overlap in time. Moreover, there was a big improvement time lag in VA between the eyes. Conclusion. Cessation of nab-paclitaxel could lead to resolution of CME more than STTA, although STTA had some effect. Since nab-paclitaxel has been recently approved for treating more types of malignancies, the number of the patients with this CME is expected to increase in the near future. Patients and physicians should understand this side effect and prepare for other treatment options.
目的。报告首例采用曲安奈德球周注射(STTA)治疗纳米白蛋白结合型(nab)紫杉醇所致黄斑囊样水肿(CME)的病例,并进行详细的长期随访。病例。一名39岁患有乳腺癌的日本女性在接受nab - 紫杉醇治疗时出现双眼视力下降。对其右眼持续存在的CME进行了两次STTA治疗。首次STTA治疗后,患眼的中央视网膜厚度(CRT)下降,但第二次STTA治疗后无变化。每次治疗后,另一只眼的CRT和双眼视力(VA)均无变化。然而,在第二次STTA治疗3个月后完成nab - 紫杉醇治疗后,该患者的视功能逐渐恢复。VA和CRT的改善在时间上并不重叠。此外,双眼之间VA的改善存在较大的时间滞后。结论。尽管STTA有一定作用,但停用nab - 紫杉醇比STTA更能使CME消退。由于nab - 紫杉醇最近已被批准用于治疗更多类型的恶性肿瘤,预计在不久的将来,这种CME患者的数量将会增加。患者和医生应了解这种副作用,并为其他治疗选择做好准备。